Abstract

Tuberculosis (TB) is a leading dreadful tropical disease which causes 1.5 million mortalities per year and nearly one-third of all TB cases are unreported annually. Keeping in view of the therapeutic properties of mycobactericidal agents, at present there are 20 new diagnostic test platforms, 4 anti-tubercular agents in Phase III, 7 in Phase II clinical trials, 5 in preclinical development and 3 mycobactericidal agents in Good Laboratory Practice toxicity evaluation. The End TB Strategy of World Health Organization paved a way to aggregate clinical trials reports in a unique platform. The neoteric introduction of TB-Platform for Aggregation of Clinical TB Studies (TB-PACTS) showed a great white hope of the scientific community which would ultimately benefit TB patients. In fact, TB-PACTS is an extremely important tool to combat TB by making clinical trials data easily available. The present study summarized not only the concise current status of TB but also substantial glimpse of TB-PACTS recently launched in a nutshell.

Authors and Affiliations